Hisashi Sakamaki, M.D.1, Shuichi Miyawaki, M.D.2, Shigeki Ohtake, M.D.3*, Nobuhiko Emi, M.D.4*, Fumiharu Yagasaki, MD5*, Kinuko Mitani, M.D.6*, Shin Matsuda, M.D.7*, Yuuji Kishimoto, M.D.8*, Yasushi Miyazaki, MD, PhD9, Norio Asou, M.D.10*, Masatomo Takahashi, M.D.11*, Yoshiaki Ogawa12*, Sumihisa Honda, Ph.D.13* and Ryuzo Ohno14*
1Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
2Hematology, Saiseikai Maebashi Hospital, Maebashi, Japan
3Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
4Hematology and Oncology, Fujita Health University Hospital, Toyoake, Japan
5Japan Adult Leukemia Study Group, Japan
6Hematology, Dokkyo University School of Medicine, Tochigi, Japan
7Center for hematopoietic disorders, Ohtanisinouchi Hospital, Kohriyama, Japan
8The First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
9Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasakishi, Japan
10Hematology, Kumamoto University School of Medicine, Kumamoto, Japan
11Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Japan
12Hematology and Oncology, Tokai University, Isehara, Japan
13Radiation Epidemiology, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan
14Aichi Cancer Center, Nagoya, Japan